leflunomide (arava) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Leflunomide, sold under the brand name Arava among others, is an immunosuppressive disease-modifying antirheumatic drug (DMARD), used in active moderate-to-severe rheumatoid arthritis and psoriatic arthritis. It is a pyrimidine synthesis inhibitor that works by inhibiting dihydroorotate dehydrogenase.   Wikipedia

Chemistry

  • SMILES: Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1
  • InChIKey: VHOGYURTWQBHIL-UHFFFAOYSA-N
  • Mol. Mass: 270.21
  • ALogP: 3.25
  • ChEMBL Molecule:
    leflunomide  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.1310 - $38.5140

Australia

$0.5572 - $0.8487
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

4-isoxazolecarboxamide, 5-methyl-n-(4-(trifluoromethyl)phenyl)- | 5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide | 5-methyl-n-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide | alpha,alpha,alpha-trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide | arava | avara | aventis behring brand of leflunomide | aventis brand of leflunomide | aventis pharma brand of leflunomide | fk788 | hoechst brand of leflunomide | hwa 486 | hwa-486 | leflunomida | leflunomide | leflunomide medac | leflunomidum | lefumide | lefunomide | n-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide | repso | su101 | su-101 | sulol

Organizations (108)

Research & Development (94)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (16)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (38)

Approved Indications (1)


 

Arthritis, Rheumatoid

Experimental Indications - Clinical Trial Phases 1-4 (38)


 

Arthritis, Juvenile (Phase 4)

Arthritis, Psoriatic (Phase 4)

Arthritis, Rheumatoid ()

Brain Neoplasms (Phase 3)

Breast Diseases (Phase 1/Phase 2)

Breast Neoplasms (Phase 1/Phase 2)

COVID-19 (Phase 3)

Drugs, Generic (Phase 1)

Glioma (Phase 1)

Glomerulonephritis, IGA (Phase 4)

Graft vs Host Disease (Phase 2)

Healthy Volunteers (Phase 1)

Hepatitis C (Phase 2)

HIV Infections (Phase 1)

Immunoglobulin G4-Related Disease (Phase 4)

Infections (Phase 2)

Leflunomide (Phase 1/Phase 2)

Lung Diseases (Phase 1/Phase 2)

Lupus Erythematosus, Systemic (Phase 2)

Lupus Nephritis (Phase 3)

Lymphoma (Phase 1/Phase 2)

Lymphoproliferative Disorders (Phase 2)

Melanoma (Phase 1)

Multiple Myeloma (Phase 2)

Musculoskeletal Diseases (Phase 2)

Myasthenia Gravis (Phase 3)

Neoplasms (Phase 1/Phase 2)

Pemphigoid, Bullous (Phase 2)

Polymyalgia Rheumatica (Phase 3)

Prostatic Neoplasms (Phase 2/Phase 3)

Purpura (Phase 2)

Renal Insufficiency, Chronic (Phase 4)

Sarcoma (Phase 1)

Sjogren's Syndrome (Phase 2)

Still's Disease, Adult-Onset (Phase 2)

Substance Withdrawal Syndrome (Phase 3)

Uveitis (Phase 2)

Viremia (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 86
  • # of Trial Organizations: 94

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue